Amryt Pharma PLC Holding(s) in Company and Lock-in agreement (2643N)
May 08 2018 - 2:01AM
UK Regulatory
TIDMAMYT
RNS Number : 2643N
Amryt Pharma PLC
08 May 2018
8 May 2018
AIM: AMYT
ESM: AYP
AMRYT PHARMA PLC
("Amryt" or the "Company")
Holdings in Company and Lock-in agreement
The Company was notified today that Raglan Road Capital Limited
("Raglan Road Capital"), a company in which Cathal Friel and his
wife, Pamela Iyer, own, has today sold 8,380,000 ordinary shares of
GBP0.01 each ("Ordinary Shares") at a price of 17 pence per
Ordinary Share (the "Disposal"). As a result of the Disposal Raglan
Road Capital Limited is interested, in aggregate, in 24,697,347
Ordinary Shares in the Company representing 8.99 per cent. of the
Company's issued share capital.
Cathal Friel and Raglan Road Capital have both entered into a
two year restriction on sale of their Ordinary Shares (the
"Locked-in Parties"). The Locked-in Parties have entered into
irrevocable undertakings that they will not (and will procure,
insofar as they are able, that any of their associates will not)
dispose of any interest in ordinary shares for a period of 12
months following the Disposal, save in certain very limited
circumstances. The Locked-in Parties have each also undertaken that
they will not (and will procure, insofar as they are able, that any
of their associates will not) dispose of any interest in Ordinary
Shares for a period of 12 months following the first anniversary of
the Disposal unless such disposal is effected through Shore Capital
Stockbrokers Limited ("Shore Capital"), to ensure an orderly market
("Orderly Market Period"). Any sale of Ordinary Shares during the
Orderly Market Period will be in such a manner as Shore Capital may
reasonably require with the view to the maintenance of an orderly
market.
- Ends -
Enquires:
Amryt Pharma plc +353 (1) 518 0200
Joe Wiley, CEO
Rory Nealon, CFO/COO
+44 (0) 20 7408
Shore Capital 4090
Nomad and Joint Broker
Edward Mansfield, Mark Percy, Daniel Bush
Davy +353 (1) 679 6363
ESM Adviser and Joint Broker
John Frain, Anthony Farrell
+44 (0) 20 7710
Stifel 7600
Joint Broker
Jonathan Senior, Ben Maddison
+44 (0) 20 3709
Consilium Strategic Communications 5700
Financial PR Adviser
Amber Fennell, Matthew Neal, Nicholas Brown
About Amryt Pharma plc
(www.amrytpharma.com)
Amryt Pharma is a specialty biopharmaceutical company focused on
developing and delivering innovative new treatments to help improve
the lives of patients with rare or orphan diseases.
The Company holds an exclusive licence to sell Lojuxta
(lomitapide) for adults, across the European Economic Area, Middle
East and North Africa, Switzerland, Turkey and Israel. Lojuxta is
used to treat a rare life-threatening disease called Homozygous
Familial Hypercholesterolaemia ("HoFH"). HoFH impairs the body's
ability to remove LDL cholesterol ("bad" cholesterol) from the
blood, which typically results in extremely high blood LDL
cholesterol levels, leading to aggressive and premature narrowing
and blocking of arterial blood vessels. If left untreated, heart
attack or sudden death may occur in childhood or early
adulthood.
Amryt's lead drug candidate, AP101, is currently in Phase III
clinical trials as a potential treatment for Epidermolysis Bullosa
("EB"). EB is a rare and distressing genetic skin disorder, which
causes exceptionally fragile skin. There is currently no approved
treatment and the global market opportunity for EB is estimated to
be in excess of EUR 1.3 billion.
Amryt has two earlier stage assets, AP102 and AP103. AP102 is
focused on developing novel, next generation somatostatin analogue
("SSA") peptide medicines for patients with rare neuroendocrine
diseases, where there is a high unmet medical need, including
acromegaly and Cushing's disease. AP103 is an in-licensed new gene
therapy platform, which has potential applicability across a range
of genetic disorders, including for patients with a sub-type of EB,
Recessive Dystrophic Epidermolysis Bullosa.
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLEAESXEDEPEAF
(END) Dow Jones Newswires
May 08, 2018 02:01 ET (06:01 GMT)
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From Apr 2024 to May 2024
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From May 2023 to May 2024